Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire · Oct 2, 2026
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic CancerGlobeNewsWire · Sep 28, 2026
Immuneering to Present at the ESMO Congress 2026GlobeNewsWire · Sep 24, 2026
Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRXDefense World · Sep 24, 2026
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended SurvivalGlobeNewsWire · Sep 10, 2026
Immuneering to Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 3, 2026Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.26 | -$0.27 | Miss |
| May 15, 2026 | -$0.30 | -$0.21 | Beat |
| Mar 6, 2026 | -$0.31 | -$0.18 | Beat |
| Nov 12, 2025 | -$0.37 | -$0.38 | Miss |
| Aug 13, 2025 | -$0.40 | -$0.40 | Beat |
| May 5, 2025 | -$0.41 | -$0.42 | Miss |